All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2026-P-1793
Request that the FDA determine whether the drug product Phenylephrine Hydrochloride in 0.9% Sodium Chloride Injection; 40 mg/250 mL (160 mcg/mL) is suitable for submission in an ANDA. The listed drug upon which this petition is based is Phenylephrine Hydrochloride in 0.9% Sodium Chloride Injection; 20 mg/250 mL (80 mcg/mL), NDA 216830 owned by Dr. Reddy’s Laboratories SA. The Petitioner seeks a
Documents
3
Comments
0
Description
OPEN
Key Dates
Comment Period OpensFeb 19, 2026
Documents
| Type | Title | Status |
|---|---|---|
Other |
Keywords
CDER
Suitability Petition
Fresenius Kabi USA, LLC
determine whether the drug product
Phenylephrine Hydrochloride in 0.9%
Sodium Chloride Injection; 40 mg/250 mL
(160 mcg/mL) is suitable for submission
in an ANDA. The listed drug upon which this
Data from Regulations.gov